<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>95(5)</volume><submitter>Dorward J</submitter><funding>Africa Oxford Initiative</funding><funding>Global Challenges Research Fund</funding><funding>National Institute for Health and Care Research</funding><funding>Wellcome Trust</funding><journal>Journal of acquired immune deficiency syndromes (1999)</journal><pagination>e8-e11</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10927299</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.</pubmed_title><pmcid>PMC10927299</pmcid><funding_grant_id>216421</funding_grant_id><funding_grant_id>MIC-2016-018</funding_grant_id><funding_grant_id>216421/Z/19/Z</funding_grant_id><funding_grant_id>0007365</funding_grant_id><funding_grant_id>AfiOx-119</funding_grant_id><pubmed_authors>Bodley N</pubmed_authors><pubmed_authors>Samsunder N</pubmed_authors><pubmed_authors>Hayward G</pubmed_authors><pubmed_authors>Sookrajh Y</pubmed_authors><pubmed_authors>Singh L</pubmed_authors><pubmed_authors>Drain PK</pubmed_authors><pubmed_authors>Lessells R</pubmed_authors><pubmed_authors>Butler CC</pubmed_authors><pubmed_authors>Bulo E</pubmed_authors><pubmed_authors>Moodley P</pubmed_authors><pubmed_authors>Garrett N</pubmed_authors><pubmed_authors>Dorward J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.</name><description/><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2026-06-27T03:16:29.131Z</modification><creation>2026-06-27T03:06:07.759Z</creation></dates><accession>S-EPMC10927299</accession><cross_references><pubmed>38489494</pubmed><doi>10.1097/QAI.0000000000003385</doi></cross_references></HashMap>